The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPets at home Regulatory News (PETS)

Share Price Information for Pets at home (PETS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.60
Bid: 285.80
Ask: 286.60
Change: 3.60 (1.27%)
Spread: 0.80 (0.28%)
Open: 280.60
High: 288.60
Low: 280.60
Prev. Close: 283.00
PETS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 FY24 Trading Statement

30 Jan 2024 07:00

RNS Number : 2890B
Pets At Home Group Plc
30 January 2024
 

 

 

 

FOR IMMEDIATE RELEASE, 30 JANUARY 2024

Pets at Home Group Plc: Q3 FY24 Trading Statement

For the 12 week period to 4 January 2024

 

Resilient peak demand but below our expectations

Financial Highlights

?

Q3 consumer revenue1 up 6.0% on last year and 15.4% on a 2-year basis. Growth was supported by growing average customer spend and growth in active VIP members, up 2% YoY to 7.7m.

?

Group revenue up 4.3% in Q3 to £362.4m, with Group like-for-like2 (LFL) revenue up 4.4%.

?

Continued strong performance in our Vet Group with Q3 revenue up 13.4%, and LFL2 up 13.3%, supported by good progress in adding vet talent and by sustained growth in average spend, driven by a blend of price and a shift to more advanced procedures.

?

Retail saw Q3 revenue up 3.5% and LFL2 up 3.7%, resilient against very strong performance last year, however this growth fell below our expectations. We were pleased to see volume growth and share gains across food, against a slowing market backdrop, showing the business remains fundamentally well positioned. However, discretionary accessories trends remained soft and inflation across Retail slowed to 3.2% (from 5.6% in Q2).

?

Gross margin performance improved sequentially from H1, with strong sell through of seasonal ranges meaning we exited Q3 with a clean inventory position. Our availability levels and pricing position remain very strong, the latter improving further through the quarter.

Current Trading & Outlook

?

While Q3 saw resilient growth against a challenging comparative, growth in our Retail business was not at the levels we had expected. As such we now expect FY24 Group underlying PBT3 to be c£132m, which assumes no sequential improvement in our Retail business LFL run rate through Q4 as we trade against a period of exceptionally strong trading last year. Our expectations of our Vet Group performance are unchanged.

?

Our balance sheet remains robust and we expect to finish the year in a net cash4 position, having returned over £100m to shareholders via ordinary dividends and our ongoing share buyback.

Strategic Highlights

?

Our new digital platform build has progressed well and we will launch it to consumers in the coming weeks, having successfully trialled and tested it with a group of colleagues. The new platform offers a much improved customer experience and functionality across our app and website and is a key foundation for future growth, enabling us to deliver a succession of improvements in the years ahead.

?

Returning accessories to growth is a key priority for the business and innovation will play a central role in this. In Q3 we introduced new premium brands including Lords & Labradors and Cocopup, and launched extended lifestyle ranges from Pawsome Paws Boutique. Innovation and the introduction of new ranges that stretch our brand appeal will remain a focus over the coming year.

?

We continue to drive innovation in food, introducing new raw dog food brands across the estate, and will soon commence the roll out of Butternut Box. The transfer to Cranswick has now successfully completed.

?

Year to date we have now opened 4 new pet care centres, and completed 33 refits. Within vets, we have opened 3 new practices, completed 16 extensions and converted 8 company-owned practices to Joint Venture ownership.

?

Strong progress within vet talent, with improvements in recruitment, vacancy rate (down 33% YoY), and vet turnover, all underpinning robust consumer revenue performance. Our third physical clinical academy hub is in progress and we have made significant strides in our international recruitment.

?

We have selected our partner for our new PMS system, Provet, a leading, cloud-based system that will unlock productivity benefits for our practice partners and enable better integration of our vets into our pet care platform. Rollout of the PMS will begin in FY25, after an initial pilot, and take 2 years to complete.

?

In the year, we have fed over 1m pets for a day through our foodbank partnership with Blue Cross, and raised over £6m for charities.

Lyssa McGowan, Chief Executive Officer, commented:

"Our colleagues came together over our peak trading period to deliver a record sales performance, growing against a very strong performance in the prior year. While a slower market over peak meant our sales growth didn't quite hit the levels we expected, the business remains well positioned to benefit from long term growth in the sector as we continue to win share and grow volumes across food and deliver differentiated performance through our unique vets business.

Importantly, we will shortly follow up launching our new distribution centre with the launch of our new digital platform, in line with our target. Our new digital platform is a key foundation of our growth strategy, bringing vastly improved user experience to our consumers, and creating opportunities to improve cross-sell into accessories and further grow share of wallet. With these foundations now in place we are well positioned for the future."

Conference Call

Management will host a Q&A conference call for analysts and investors at 9.30am. To join the call in

listen-only mode, please click on the following link (https://brrmedia.news/PETS_Q3FY24). Those wishing to participate in the Q&A session should email pets@accordience.com for call details. A recording will be available at https://www.petsathomeplc.com/investors/results-presentations/.

 

Our next scheduled update will be a pre-close update at the end of March.

1.

Consumer revenue includes total revenue across the Group including consumer sales made by Joint Venture vet practices, and therefore differs to the fee income recognised within Vet Group revenue.

2.

Like-for-like revenue comprises total revenue in a financial period compared to revenue achieved in a prior period, for stores, omnichannel operations, grooming salons, and vet practices that have been trading for 52 weeks or more.

3.

Underlying profit before tax (PBT) is based on pretax profit before the impact of certain costs or incomes that derive from events or transactions that fall outside the normal activities of the Group and are excluded by virtue of their size and nonrecurring nature, in order to reflect management's view of the performance of the Group.

4.

Net cash is defined as cash and cash equivalents less loans and borrowings.

 

Investor Relations Enquiries

Pets at Home Group Plc:

 

Andrew Porteous, Director of Investor Relations

+44 (0) 7740 361 849

Chris Ridgway, Head of Investor Relations

+44 (0) 7788 783 925

 

Media Enquiries

Pets at Home Group Plc:

Natalie Cullington, Head of Communications

+44 (0) 7974 594 701

Citigate Dewe Rogerson:

Angharad Couch

+44 (0) 7507 643 004

 

About Pets at Home

Pets at Home Group Plc is the UK's leading pet care business, providing pets and their owners with the very best advice, products

and care. Pet products are available online or from over 450 pet care centres, many of which also have vet practices and grooming

salons. The Group also operates a leading small animal veterinary business, with over 440 veterinary general practices located both

in our pet care centres and in standalone locations. For more information visit: https://www.petsathomeplc.com/

 

Disclaimer

This trading statement does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Pets at Home Group Plc shares or other securities nor should it form the basis of or be relied on in connection with any contract or commitment whatsoever. It does not constitute a recommendation regarding any securities. Past performance, including the price at which the Company's securities have been bought or sold in the past, is no guide to future performance and persons needing advice should consult an independent financial adviser. Certain statements in this trading statement constitute forward-looking statements. Any statement in this document that is not a statement of historical fact including, without limitation, those regarding the Company's future plans and expectations, operations, financial performance, financial condition and business is a forward-looking statement. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks and uncertainties include, among other factors, changing economic, financial, business or other market conditions. These and other factors could adversely affect the outcome and financial effects of the plans and events described in this statement. As a result you are cautioned not to place reliance on such forward-looking statements. Nothing in this statement should be construed as a profit forecast.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulations (Regulation (EU) No.596/2014). For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by Andrew Porteous, Director of Investor Relations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUKOARSSUAUUR
Date   Source Headline
2nd Apr 20248:29 amRNSTotal Voting Rights
26th Mar 20247:00 amRNSFY24 pre-close statement
14th Mar 202410:36 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 202410:31 amRNSResponse to CMA announcement
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20249:43 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20244:51 pmRNSHolding(s) in Company
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20247:00 amRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSQ3 FY24 Trading Statement
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 20247:00 amRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20247:00 amRNSTransaction in Own Shares
18th Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 20247:00 amRNSTransaction in Own Shares
16th Jan 20247:00 amRNSNotification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.